The importance of KRAS status in managing metastatic colorectal cancer Stephen LeongS. Gail EckhardtWells Messersmith OriginalPaper 14 July 2009 Pages: 129 - 134
Evolving end points for clinical trials in advanced colorectal cancer Sharlene GillDaniel J. Sargent OriginalPaper 14 July 2009 Pages: 135 - 139
Radiation to the liver for hepatic metastases from colorectal cancer: Stereotactic radiotherapy and radioactive microspheres Stephen L. HarrisJoel E. Tepper OriginalPaper 14 July 2009 Pages: 140 - 147
Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer Max VergoHalla NimeiriAl B. Benson III OriginalPaper 14 July 2009 Pages: 151 - 157
Risk assessment and adjuvant systemic therapy in resected stage II colon cancer Veena ShankaranPolina KhrizmanAl B. Benson III OriginalPaper 14 July 2009 Pages: 158 - 165
Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07 Corrado BoniThierry AndréAimery de Gramont OriginalPaper 14 July 2009 Pages: 166 - 170
Incidence of KRAS status in ongoing adjuvant trials in colon cancer Julien TaiebPierre Laurent-PuigSteven Alberts OriginalPaper 14 July 2009 Pages: 171 - 178